Halozyme Therapeutics has had an impressive run over the past six months as its shares have beaten the S&P 500 by 24.3%. The stock now trades at $75.77, marking a 35.8% gain. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 22.1% year on year to $354.3 million. The company’s full-year revenue guidance of $1.34 billion at the midpoint came in 1.5% above analysts’ estimates. Its non-GAAP profit of $1.72 per share was 5.5% above analysts’ consensus estimates.
San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025. This significant milestone comes on the heels of a robust third-quarter 2025 earnings report that dramatically exceeded analyst expectations,
Halozyme Therapeutics (HALO) offers a high-growth momentum play with strong earnings, rising profit margins, and a technical breakout setup for potential entry.
Halozyme Therapeutics (HALO) is a strong value stock with high profitability, a healthy balance sheet, and solid growth, all while trading at an attractive valuation.
Halozyme Therapeutics offers strong growth and profitability at an attractive valuation. Its ENHANZE drug delivery tech drives revenue, with a low P/E ratio for an affordable growth stock.
